- The 2025 LogiPharma AI Report reveals a shift in pharmaceutical supply chains from real-time monitoring to predictive AI tools, including machine learning for risk alerts, blockchain technology, and demand sensing at product launches.
- Industry leaders are prioritizing multi-layered resilience, with increased investment in cold chain infrastructure, comprehensive quality assurance, and proactive risk prevention to protect patient safety.
- Key barriers to wider AI adoption include internal resistance (70%), regulatory uncertainty, and a lack of skilled talent and AI literacy.
A report commissioned by LogiPharma has revealed significant changes in the way pharmaceutical supply chains are adopting AI, reflecting an industry in transition.
the LogiPharma AI Report 2025based on a survey of 100 senior supply chain leaders across Europe and North America, shows that AI adoption has evolved, with investment shifting from monitoring to intelligence.
Ben Sharples, LogiPharma Conference Director, said: “In the past year, AI has evolved from pilot to practical deployment, with its applications touching almost every area of the pharmaceutical supply chain.
“In the context of an increasingly unpredictable world, the industry is focused on ensuring it is prepared for complexity, moving towards multi-layered resilience, prevention, forecasting and contingency.”
The report’s findings indicate that although investment remains flat in real-time monitoring, especially regarding vulnerabilities in cold chain logistics, AI adoption is now stronger in the area of predictive intelligence. The report found that 64% of respondents were evaluating blockchain and chain of custody technologies, along with data analytics platforms (54%) and AI/ML for predictive risk alerts (53%), indicating a move towards a more proactive approach to resilience.
“Pharmaceutical products protect lives, and even small changes in temperature can affect effectiveness or cause total damage,” says Jansen Stafford, Regional Head of Cargo Europe, one of the experts who contributed to the report. “Challenges include intermodal shifts, customs delays, and environmental extremes. Therefore, the focus has shifted from basic compliance to ensuring total quality, through dedicated infrastructure, expert staff, and proactive monitoring to stay ahead of risks.”
However, while future-readiness and resilience remain top of mind for stakeholders, the report found that the most common AI investment in industry is demand sensing when launching new products, demonstrating growing interest and confidence in the predictive and creative capabilities of AI technology.
Qualitative responses confirmed this as well, with many emphasizing AI’s potential to enhance patient outcomes, from personalized medication delivery to faster drug recalls and counterfeit product detection. But, according to participants, this input must be balanced with human oversight, with AI seen not as a decision maker, but rather as a trusted collaborator.
“Customers are looking for transformative solutions that can redefine how their operations are managed, not just tools to process transactions,” says Shabbir Dahod, president and CEO of TraceLink. “What we need – and what we are creating at TraceLink – is an operating model in which AI is not a proven tool, but a trusted colleague that helps leaders respond to events faster and with greater confidence.”
Trust remains at the heart of industry discussions around the use of AI, with internal resistance (70%) representing one of the biggest challenges to wider implementation. This reflects a broader cultural mistrust Artificial intelligence in the workplaceThis is a challenge that is being addressed at the governmental level around the world. Other barriers highlighted included regulatory uncertainty (58%) and a lack of skilled talent or AI knowledge (48%).
Artificial Intelligence and digital transformation will be a key topic of conversation during the upcoming LogiPharma conference in Vienna, 14y To 16y April 2026.
“LogiPharma sees the convergence of supply chain and logistics professionals from around the world, creating an opportunity for sector leaders to exchange views and best practices,” says Ben Sharples. “As AI technology advances and the industry works to harness its potential, it has never been more important that we come together as a group to ensure we maximize the potential benefits – not just for the supply chain, but ultimately for patients.”
About the Author
